People around the globe suffer from a myriad of rare diseases, many of which have no cure or limited treatment options. Many patients have been living without hope of a significant improvement in ...

“Antisense” drugs that aim to shut down disease-related genes have long been out of favor, and these days live in the shadow of a hotter and newer technology — RNA interference — that does much the ...

When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...

The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis (ALS) - blocking production of a mutant protein that causes an inherited form of the progressive ...

Economic Moat Ionis has proprietary antisense oligonucleotide technology that has led to three approved RNA-based drugs and a steadily growing pipeline, which together support the firm's intangible ...

CARLSBAD, Calif., April 4, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its partner, AstraZeneca, today announced positive data from the ...

Isis Pharmaceuticals (www.isispharm.com) has developed an antisense drug candidate that continues to show potential in treating patients with cardiovascular diseases by reducing cholesterol, LDL-C, as ...

Sept 9 (Reuters) - Biogen Idec has agreed to pay another $100 million upfront to Isis Pharmaceuticals Inc as part of a broad collaboration to develop new medicines for neurological disorders, the ...

So far, 2013 has been a good year for antisense technology. In fact, it’s been great. In January the FDA OK’d Isis Pharmaceuticals’ Kynamro™ (mipomersen sodium), the only currently marketed antisense ...

Where is a scientist to begin studying a newly cloned gene that has no apparent function or phenotype? A common approach for obtaining functional clues is to inactivate the gene either in vitro or in ...

Unmodified starches present a problem to the frozen food industry as they tend to result in poor texture upon cycles of freeze-thawing. In March Nature Biotechnology, Stephen Jobling and colleagues ...